Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5726MR)

This product GTTS-WQ5726MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5726MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3172MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ7149MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ7514MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ3283MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ1221MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ4357MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ118MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 11F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW